On April 2, 2019, the Federal Food and Drug Administration (FDA) issued a statement and announced a public hearing on consumer products derived from cannabis and its components, including cannabidiol (CBD). Recognizing the need to provide clarity on the authority of FDA to regulate these products, and what pathways are available for marketing them, the agency outlined its next steps:

  • A¬†public hearing¬†will be held on May 31, and written comments are being sought from the public.
  • FDA is forming a high-level internal agency working group to explore potential